Early testing of a vaccine targeting the PfRh5 malaria protein has shown promise in animal studies, and human clinical trials are the next step, an Oxford researcher said. "We have found a way of making antibodies that kill all different strains of malaria parasites," said Dr. Sandy Douglas, primary author of a study reporting the development.

Full Story:

Related Summaries